Ascentage Pharma Group International
AAPG
Ascentage Pharma Group International is a clinical-stage biotechnology company focused on discovering, developing, and commercializing therapies for cancers, chronic hepatitis B virus, and age-related diseases. Its current portfolio centers on novel small-molecule drugs designed to regulate programmed cell death pathways, with emphasis on hematologic malignancies and other oncology indications. The company’s development pipeline includes product candidates such as olverembatinib, a BCR-ABL inhibitor, along with additional therapies targeting apoptosis-related pathways and other cancer-relevant mechanisms. Ascentage Pharma Group International operates as an integrated biopharmaceutical business, supporting research, clinical development, and commercialization activities across major markets including Mainland China and the United States. Headquartered in Suzhou, China, the company plays a specialized role in the global biotechnology sector by advancing targeted treatment options for diseases with significant unmet medical needs.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
¥574M
▼ -41.5% YoY
Net Income (TTM)
-¥1.24B
▼ -206.4% YoY
Op. Margin
-208.61%
▼ -170.9pp YoY
ROIC
-36.00%
▼ -20.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-¥1.20B
▼ -785.9% YoY
Op. Cash Flow (TTM)
-¥1.17B
▼ -954.4% YoY
Net Debt
-¥485M
Net Cash Position
Cash & Equiv.
¥2.46B
3Y CAGR: +39.9%
Continue Research
Peers
Biotechnology · Pick stocks to compare with AAPG
Ascentage Pharma Group International (AAPG) in four numbers
Questions about Ascentage Pharma Group International
Is Ascentage Pharma Group International (AAPG) overvalued?
At $11.97, Ascentage Pharma Group International's price is 421% above the $2.30 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Ascentage Pharma Group International's fair value?
Intrinsiqq's calculator puts Ascentage Pharma Group International's fair value at $2.30 a share. It grows revenue per share 5% a year for 5 years, applies an exit P/S of 3, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $1.72. Every input can be changed on the Intrinsic Value tab.
Is Ascentage Pharma Group International a high-quality business?
Ascentage Pharma Group International scores 40 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 5 checks computed from company filings. Its best check is revenue growth at 39.9%, and its weakest is return on capital at -36.0%. The Quality tab shows every check against its target.
Does Ascentage Pharma Group International (AAPG) pay a dividend?
No. Ascentage Pharma Group International (AAPG) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Over the last twelve months it returned cash through share buybacks instead, equal to a 0.1% buyback yield. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing AAPG
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.